Tag
President Trump signed an executive order directing the FDA to expedite psychedelic drug access through breakthrough designation and right-to-try pathways. FDA Commissioner Marty Makary said three priority review vouchers for serotonin 2a agonists will be issued next week, with broader agency decisions expected this
A Cochrane review has intensified debate over the clinical value of amyloid-targeting Alzheimer's therapies, while the FDA moves to reconvene advisory panels on compounded peptides it had restricted. Eli Lilly plans to submit its oral GLP-1 drug Foundayo to the FDA by end of Q2 after a positive cardiovascular outcomes
Tag
President Trump signed an executive order directing the FDA to expedite psychedelic drug access through breakthrough designation and right-to-try pathways. FDA Commissioner Marty Makary said three priority review vouchers for serotonin 2a agonists will be issued next week, with broader agency decisions expected this
2mo ago · 1 min · Policy & Government
A Cochrane review has intensified debate over the clinical value of amyloid-targeting Alzheimer's therapies, while the FDA moves to reconvene advisory panels on compounded peptides it had restricted. Eli Lilly plans to submit its oral GLP-1 drug Foundayo to the FDA by end of Q2 after a positive cardiovascular outcomes
2mo ago · 1 min · Technology
— End of feed —